Association Européenne de Psychiatrie and Synthélabo

2 European AEP grants

in neuropsychiatry sponsored by Synthélabo to the value of 150 000 French Francs each.

Each grant to the value of 150,000 French Francs

The third award of the AEP grants will be in September 1998

(based upon the period from July 1996 to September 1998)

Synthelabo is today present in all major areas of psychiatry and CNS is considered as one of their privileged fields of research.

Synthelabo wishes to confirm their involvement as a European partner in the training of young scientists and practitioners in psychiatry and other medical fields.

t is in this context Synthelabo and AEP d in their effort opean grants iatry.

Objectives

Fundamental research in psychosis:

- biological psychiatry
- clinical psychiatry
- psychopathology

as areas of interest to the European psychiatric-scientific community.
The studies may necessitate specific training abroad and the grant could be used as an « exchange award ».

Candidates

This prize is open to all researchers and/or motivated teams, supported by a leading figure of the psychiatric-scientific community and to all European countries (EU and non-EU).

Rules

The researcher must submit to the jury a project description of 10 to 15 pages in one of the 3 official languages of the AEP (English, French or German) accompanied by an English summary.

He/she must be supported by a member of the AEP and his/her paper accompanied by a curriculum vitae and a list of his/her publications.

After a two months review period the jury will announce the 2 theses selected and the first part of the grant, 50,000 FF, will be awarded in September 1997.

The second part, 100,000 FF, will be awarded at the AEP Congress in September 1998, by the President of the Association. The selected studies must be announced at the November meeting of the Association and be presented at the AEP Congress 1998.

Jury

The jury consists of :

The President of AEP

The Past-President

The General Secretary

The Section Adviser

as well as 3 members designated by the AEP from countries not previously represented and a member of Synthelabo to act as the secretary to the jury.

Composition of the application file

It should include :

- The typed project description in English, French or German with a clear abstract in English,
- An attestation of support by a member of the AEP,
- A curriculum vitae with age and address,
- An application letter addressed to the President of the AEP and to Doctor Garreau at the following address.

Doctor Garreau
AEP Grants
Synthélabo
22 avenue Galilée
92350 Le Plessis Robinson
France

Telephone : (1) 45.37.57.72
Fax : (1) 45.37.59.63

candidates : Projects are to be submitted before November 30th, 1996 to ary of the jury: after this date applications will not be considered.

https://doi.org/10.1017/S0924933800285210 Published online by Cambridge University Press

IMOVANE,
24 hours in harmony.



International multi-centre study confirms that Imovane improves the Quality of Life.

This study was conducted in 5 different European countries, in 86 different locations and included 458 patients.

The main objective was to study patients' quality of life during two weeks of continuous therapy with IMOVANE, which were then followed by a further six weeks of therapy on request.

Measurements recorded for four different quality of life criteria (*sleep, physical condition, daily activity, social life*) were all significantly in favour of IMOVANE.

24 hours in harmony is what IMOVANE promises. This comes as a result of the interactions between the separate measurements achieved in this study. When a patient sleeps better, his sleep will be more restorative ; he will awake refreshed, and his daily activities and social life will be improved.

Presentation : White elliptical tablets containing 7.5 mg zopiclone. The tablets also contain lactose. **Pharmacology** : Zopiclone is a non-benzodiazepine hypnotic, a member of the cyclopyrrolone group of compounds which is structurally unrelated to existing hypnotics and tranquilisers. **Indications** : for short term treatment of insomnia which is debilitating or causing severe distress for the patient. A course of treatment should not be longer than 4 weeks. **Dosage and Administration** : Adults : One 7.5 mg tablet shortly before retiring. This may be increased to two tablets for patients who do not respond to the lower dose. Elderly : A lower dose of 3.75 mg zopiclone is recommended initially. The dosage subsequently may be increased if clinically necessary. Children : Not recommended. **Contraindications** : Pregnancy lactation. **Precautions** : Hepatic insufficiency : A lower dose of 3.75 mg zopiclone is recommended. Risk of dependence : Minimal risk if treatment limited to not more than 4 weeks. Risk may be increased in those who abuse drugs or alcohol, or who have marked personality disorders. **Withdrawal** : Withdrawal effects unlikely, although all patients should be monitored. **Interactions** : Alcohol, CNS depressants, tricyclic antidepressants. **Adverse effects** : Most frequently, mild bitter or metallic after-taste, mild gastrointestinal disturbances. Occasionally drowsiness on waking, dizziness, light-headaches and uncoordination. Although residual effects are rare, patients should not drive or operate machinery until it is established that performance is unimpaired. Psychological and behavioural disturbances and allergic manifestations such as urticaria or rash have been reported. **Legal Category** : POM. **Pharmaceutical Precautions** : Protect from light. Store in a dry place below 30°C.

RHÔNE-POULENC RORER

AEP

EUROPEAN PSYCHIATRY:
A Force for the Future

7-12 July 1996

LONDON LONDRES LONDRA

is supported by an educational grant from

JANSSEN-CILAG *and* Organon

conifer

congress information systems

AEP, Janssen-Cilag, Organon and Excerpta Medica have collaborated in order to provide the Conifer electronic information services on several interactive terminals. Conifer enables you to browse through the congress abstracts and scientific programme and allows you to print out selected abstracts at the Janssen-Cilag/Organon exhibit.

Janssen Pharmaceutica N.V., B-2340 Beerse, Belgium